Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 2/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1908151 | 0.87 | TACR3 (0.37) | MEN1KMT2ATACR3NTRK1PDE2A | |
| SCHEMBL1902064 | 0.80 | SCN9A (0.34) | TACR3NTRK1PDE2AHDAC3HDAC1 | |
| SCHEMBL1905401 | 0.74 | TACR3 (0.36) | TACR3PDE2A | |
| SCHEMBL1905448 | 0.73 | TACR3 (0.38) | TACR3MAPK1PDE2AHDAC3HDAC1 | |
| SCHEMBL14118444 | 0.72 | CHEK1 (0.37) | TACR3PDE2A | |
| SCHEMBL1902380 | 0.72 | EGFR (0.38) | MEN1KMT2ATACR3PDE2A | |
| SCHEMBL1907935 | 0.72 | PDE2A (0.39) | TACR3PDE2A | |
| SCHEMBL1904052 | 0.72 | EGFR (0.37) | TACR3PDE2A | |
| SCHEMBL1903130 | 0.71 | TACR3 (0.34) | TACR3MAPK1PDE2AHDAC3HDAC1 | |
| SCHEMBL1902848 | 0.71 | TACR3 (0.37) | TACR3MAPK1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | MEN1 1472/4885KMT2A 2565/4885ERAP1 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.